Skip to main content

Optic Neuritis

Ophthalmology
2
Pipeline Programs
10
Companies
6
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Ophthalmology is a $3.7B market with a mature, consolidating portfolio dominated by glaucoma treatments and emerging corneal/retinal therapies.

$3.7B marketMature→ Stable30 products15 companies

Key Trends

  • Glaucoma therapeutics (prostaglandin analogs, adrenergic agents) represent 60%+ of spending but face patent cliffs 2028-2034
  • Innovative mechanisms (NGF agonists, LFA-1 antagonists, RTKIs) gaining traction in dry eye and retinal disease segments
  • Heavy trial activity (2,656 total) skewed toward Phase 4 (369) and Phase 3 (442), indicating mature clinical development landscape

Career Verdict

Ophthalmology offers stable mid-career opportunities with strong Commercial and Medical Affairs salaries, but limited innovation catalysts and significant patent cliff risk warrant careful timing of entry.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1LUMIGANDeclining
$697M
AbbVie·LOE_APPROACHING
#2OXERVATEStable
$493M
Unspecified·PEAK
#3XIIDRAStable
$473M
Bausch + Lomb·PEAK7.6yr
#4INLYTAGrowing
$467M
Pfizer·PEAK11.2yr
#5HUMIRADeclining
$258M
AbbVie·LOE_APPROACHING

Drug Class Breakdown

Prostaglandin Analogs (Bimatoprost)
$697M(19%)

mature, losing exclusivity

Nerve Growth Factor Agonists
$493M(13%)

peak growth in corneal disease

LFA-1 Antagonists (Dry Eye)
$473M(13%)

sustained peak sales

Receptor Tyrosine Kinase Inhibitors
$467M(13%)

expanding in retinal indications

Alpha-2 Adrenergic Agonists
$362M(10%)

mature, multiple LOE approaching

Combination Therapies (Brimonidine/Timolol)
$232M(6%)

mature, losing exclusivity

Complement Inhibitors
$223M(6%)

mature immunology approach

Career Outlook

Stable

Ophthalmology offers predictable mid-career growth with strong Commercial ($158K) and Medical Affairs ($247K) compensation but faces structural headwinds: patent cliffs 2028-2034 eliminate $97M in revenue, glaucoma franchise maturity limits blockbuster potential, and modest trial volume (2,656) signals incremental R&D expansion. Best suited for professionals seeking stable roles in established therapeutic areas rather than disruptive innovation.

Breaking In

Enter via Clinical Operations or Commercial analyst roles at CROs (Syneos 210 jobs) or large diagnostics players (Labcorp 904) to build domain expertise before targeting pharma MSL/Medical Affairs positions.

For Experienced Professionals

Experienced professionals should prioritize Medical Affairs and Market Access roles leveraging mature market knowledge; avoid product-specific expertise in glaucoma due to patent cliff concentration, and consider adjacent areas (retinal, corneal) where innovation catalysts remain.

In-Demand Skills

Glaucoma/dry eye clinical expertise and key opinion leader relationshipsRegulatory navigation for mature small-molecule formulations and device combinationsMarket access and reimbursement strategy (high generic/biosimilar pressure)

Best For

Medical Science Liaison (MSL) — strong $247K average salary, KOL interface criticalCommercial/Brand Manager — competitive $158K salaries, established product lifecycle managementClinical Operations Manager — high hiring volume (409 jobs), trial coordination in Phase 4-heavy pipeline

Hiring Landscape

$59K-$247K

Ophthalmology hiring (3,202 jobs) is distributed across diagnostics/devices (Labcorp 904, Abbott 348) and pharma commercial functions rather than concentrated in R&D. Top pharmaceutical employers (Pfizer 60, AstraZeneca 100, Regeneron 168) show modest pharma-specific headcount relative to market size, suggesting outsourced CRO and distributor dependency. Medical Affairs ($247K avg salary) commands premium compensation, signaling high barrier to entry but strong mid-career upside.

3,202
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

904Growing
348Stable
168Growing
219Stable

By Department

Clinical Operations(13%)
$150K
Commercial(10%)
$158K
Medical Affairs(3%)
$247K
R&D(6%)
$145K
Engineering(9%)
$112K

Clinical Operations and Commercial roles offer entry-level stability ($150K-$158K); Medical Affairs commands premium salaries ($247K) but requires advanced credentials; limited R&D hiring (207 jobs) suggests constrained innovation investment.

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Accure Therapeutics
Accure TherapeuticsSpain - Barcelona
1 program
1
BN201Phase 11 trial
Active Trials
NCT03630497Completed48Est. Feb 2019
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
1
Lipoic AcidPhase 11 trial
Active Trials
NCT01294176Completed31Est. Nov 2016
Sandoz
SandozAustria - Kundl
1 program
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)N/A1 trial
Active Trials
NCT05017142Recruiting500Est. Jan 2071
Roche
RocheSTAVANGER NORWAY, Norway
1 program
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)N/A
Novartis
NovartisBASEL, Switzerland
1 program
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)N/A
Biogen
BiogenCAMBRIDGE, MA
1 program
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)N/A
Sanofi
SanofiPARIS, France
1 program
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)N/A
argenx
argenxBelgium - Zwijnaarde
1 program
Efgartigimod AlfaPHASE_21 trial
Active Trials
NCT06453694Recruiting20Est. Jul 2027
Oculis
OculisZUG, Switzerland
1 program
OCS-05 +SoCPHASE_21 trial
Active Trials
NCT04762017Completed36Est. Sep 2024
Teva
TevaIsrael - Petach Tikva
1 program
Glatiramer AcetatePHASE_31 trial
Active Trials
NCT00856635Completed44Est. Feb 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
TevaGlatiramer Acetate
argenxEfgartigimod Alfa
OculisOCS-05 +SoC
Accure TherapeuticsBN201
Oregon TherapeuticsLipoic Acid
SandozSwiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Clinical Trials (6)

Total enrollment: 679 patients across 6 trials

NCT00856635TevaGlatiramer Acetate

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)

Start: Feb 2009Est. completion: Feb 201144 patients
Phase 3Completed
NCT06453694argenxEfgartigimod Alfa

Efgartigimod for the Treatment of Acute Optic Neuritis

Start: Aug 2025Est. completion: Jul 202720 patients
Phase 2Recruiting

OCS-05 in Patients With Optic Neuritis

Start: Feb 2021Est. completion: Sep 202436 patients
Phase 2Completed

BN201 SAD MAD Study in Healthy Subjects

Start: May 2018Est. completion: Feb 201948 patients
Phase 1Completed

Lipoic Acid as a Treatment for Acute Optic Neuritis

Start: Jan 2011Est. completion: Nov 201631 patients
Phase 1Completed
NCT05017142SandozSwiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Start: Apr 2020Est. completion: Jan 2071500 patients
N/ARecruiting

Related Jobs in Ophthalmology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 679 patients
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.